Schonfeld Strategic Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,905	Closed	-$558K	–	2209
2025 Q4	$558K	Buy	+25,905	New	+$503K	﹤0.01%	1354
2025 Q1	–	Sell	-47,644	Closed	-$501K	–	2200
2024 Q4	$501K	Sell	47,644 -22,256	-32%	-$270K	﹤0.01%	1394
2024 Q3	$917K	Buy	69,900 +158	+0.2%	+$2.41K	0.01%	1192
2024 Q2	$981K	Sell	69,742 -252,258	-78%	-$4.11M	0.01%	1219
2024 Q1	$5.44M	Buy	+322,000	New	+$4.8M	0.04%	613
2020 Q3	–	Sell	-57,300	Closed	-$463K	–	1356
2020 Q2	$463K	Buy	+57,300	New	+$505K	0.01%	830

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Schonfeld Strategic Advisors's AVDL Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 25,905 shares — an estimated $558K sold.

Schonfeld Strategic Advisors first reported a position in AVDL in Q2 2020 and held it in 6 quarters. The position peaked at $5.44M in Q1 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Schonfeld Strategic Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Schonfeld Strategic Advisors sold 25,905 Avadel Pharmaceuticals shares in Q1 2026, an estimated $558K.
Schonfeld Strategic Advisors first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Schonfeld Strategic Advisors's Avadel Pharmaceuticals position peaked at $5.44M in Q1 2024.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.